Compare WTI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTI | OVID |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.7M | 522.6M |
| IPO Year | 2004 | 2017 |
| Metric | WTI | OVID |
|---|---|---|
| Price | $4.75 | $2.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | ★ 7.2M | 2.1M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $487,096,000.00 | $7,252,000.00 |
| Revenue This Year | $11.73 | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.34 | $0.27 |
| 52 Week High | $4.58 | $3.11 |
| Indicator | WTI | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 47.65 |
| Support Level | $1.67 | $2.56 |
| Resistance Level | N/A | $2.72 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 97.48 | 11.69 |
W&T Offshore Inc is an an independent oil, NGL and natural gas producer with all of its operations offshore in the Gulf of America. The company is active in the exploration, development and acquisition of oil and natural gas properties. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion. The company has its operations in Mississippi Canyon; Ewing Bank; Ship Shoal; Garden Banks; and Mobile Bay Complex.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.